Science & health
FDA weighs looser enforcement for unproven peptide drugs, report says
The FDA has submitted an interim policy on peptide drugs for White House review, potentially allowing the agency to use enforcement discretion toward some products that specialty pharmacies want to compound. The proposal’s details are not public. The report says FDA scientists previously found that a dozen popular injectable peptides lacked sufficient safety and efficacy evidence and posed risks, while sellers continue making unsupported wellness claims. The Department of Health and Human Services did not respond to questions.
Editorial summary · Publisher article
What matters
- The policy filing appears on an Office of Management and Budget website but does not describe the proposed rules.
- The drugs were removed in 2023 from the list of products eligible for specialty-pharmacy compounding.
- Peptides are particularly popular among figures associated with Robert F. Kennedy Jr.’s health movement.
Context & caveats
- The proposed policy is not public, and key details come from people familiar with it rather than an official statement.
Why this made the edition
The report identifies an official FDA policy review, explains the regulatory mechanism under consideration, supplies prior safety concerns and distinguishes documented filings from anonymous-source claims.
Source material